Related references
Note: Only part of the references are listed.Glucocorticoid use is associated with an increased risk of hypertension
Ruth E. Costello et al.
RHEUMATOLOGY (2021)
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Masayoshi Harigai et al.
MODERN RHEUMATOLOGY (2020)
Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Siddharth Singh et al.
ARTHRITIS CARE & RESEARCH (2020)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study
Elena Nikiphorou et al.
HEART (2020)
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
Philip Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Cardiovascular risk in persons at risk of developing rheumatoid arthritis
Laurette van Boheemen et al.
PLOS ONE (2020)
Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis
Wenhui Xie et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
M. C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, AND HEALTH-RELATED QUALITY OF LIFE, AND REDUCED FATIGUE OVER TIME IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ARE METHOTREXATE-NAIVE: RESULTS FROM THE FINCH 3 STUDY
R. Alten et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Josef S. Smolen et al.
JOURNAL OF RHEUMATOLOGY (2019)
Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
Masayoshi Harigai
RHEUMATOLOGY (2019)
The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: A systematic literature review
Francesco Ursini et al.
AUTOIMMUNITY REVIEWS (2019)
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
Jacques-Eric Gottenberg et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials
Wenhui Xie et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
Christina Charles-Schoeman et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients
Fenglong Xie et al.
ARTHRITIS CARE & RESEARCH (2019)
Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells
Xiaoyang Yang et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2019)
Identification of a 3′-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study
Raquel Lopez-Mejias et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?
Fabiola Atzeni et al.
AUTOIMMUNITY REVIEWS (2019)
Upadacitinib for the treatment of rheumatoid arthritis
Lina Serhal et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Long-Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five-Year Observational Study
Kevin L. Winthrop et al.
ARTHRITIS CARE & RESEARCH (2019)
Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study
Rishi J. Desai et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Peter C. Taylor et al.
ARTHRITIS & RHEUMATOLOGY (2019)
SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
Paul Emery et al.
RHEUMATOLOGY (2019)
Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials
Wenhui Xie et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2019)
Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection
Julien Henry et al.
RHEUMATOLOGY (2018)
Arterial Inflammation Detected With 18F-Fluorodeoxyglucose-Positron Emission Tomography in Rheumatoid Arthritis
Laura Geraldino-Pardilla et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
Peter C. Taylor et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis
C. Charles-Schoeman et al.
ATHEROSCLEROSIS (2018)
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Ian C. Scott et al.
DRUG SAFETY (2018)
The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review
Michael Nurmohamed et al.
DRUG SAFETY (2018)
Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease
Yinzhu Jin et al.
JOURNAL OF RHEUMATOLOGY (2018)
Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications
Bryant R. England et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications
Bryant R. England et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Rheumatoid arthritis
Josef S. Smolen et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
Fabio Cacciapaglia et al.
MEDIATORS OF INFLAMMATION (2018)
Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis
Claire Rempenault et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact?
Marie Holmqvist et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis
Cynthia S. Crowson et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap
Diane Lacaille et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
2016 update of the EULAR recommendations for the management of early arthritis
Bernard Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Filgotinib for the treatment of rheumatoid arthritis
Peter C. Taylor et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Anterior ST-elevation myocardial infarction induced by rituximab infusion: A case report and review of the literature
K. Sharif et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
Tilo Grosser
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study
Kensuke Kume et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis
Joel M. Kremer et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis
Francesco Ursini et al.
SCIENTIFIC REPORTS (2017)
Temporal trends in prevalence, incidence, and mortality for rheumatoid arthritis in Quebec, Canada: a population-based study
Sonia Jean et al.
CLINICAL RHEUMATOLOGY (2017)
Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis
Jamie Robertson et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study
Elke E. A. Arts et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice
Zaicun Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis
Orit Schieir et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk
Elena Myasoedova
CURRENT OPINION IN RHEUMATOLOGY (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Opposing roles of B lymphocyte subsets in atherosclerosis
Tin Kyaw et al.
AUTOIMMUNITY (2017)
Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia
Maaike Kockx et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do
Zoltan Szekanecz et al.
AUTOIMMUNITY REVIEWS (2016)
Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers
Raquel Lopez-Mejias et al.
AUTOIMMUNITY REVIEWS (2016)
Novel mechanisms of atherosclerosis and cardiovascular repair
Thomas F. Luscher
EUROPEAN HEART JOURNAL (2016)
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
Christina Charles-Schoeman et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist
Christina Charles-Schoeman et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Proatherogenic Cytokine Microenvironment in the Aortic Adventitia of Patients With Rheumatoid Arthritis
Ammad Ahmed et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis
Paul A. MacMullan et al.
CLINICAL RHEUMATOLOGY (2016)
Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis
Frank Verhoeven et al.
ARTHRITIS RESEARCH & THERAPY (2016)
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
Camille Roubille et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Inflammation and plaque vulnerability
G. K. Hansson et al.
JOURNAL OF INTERNAL MEDICINE (2015)
Abatacept Improves Whole-Body Insulin Sensitivity in Rheumatoid Arthritis An Observational Study
Francesco Ursini et al.
MEDICINE (2015)
Atherosclerosis in rheumatoid arthritis: is it all about inflammation?
Sarah Skeoch et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species
Rajeshwary Ghosh et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2015)
Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
Christina Charles-Schoeman et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism
Nicoletta Ronda et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions
Justin C. Mason et al.
EUROPEAN HEART JOURNAL (2015)
Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials A Systematic Review and Meta-Analysis
Alejandro Souto et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study
Iain B. McInnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system
I. A. M. van den Oever et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Increased Benefit of Interleukin-1 Inhibition on Vascular Function, Myocardial Deformation, and Twisting in Patients With Coronary Artery Disease and Coexisting Rheumatoid Arthritis
Ignatios Ikonomidis et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2014)
Rheumatoid arthritis and metabolic syndrome
Gyoergy Kerekes et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study
Alper M. van Sijl et al.
PLOS ONE (2014)
Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications
Gail Kerr et al.
ARTHRITIS CARE & RESEARCH (2014)
The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study
Lotta Ljung et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Glucocorticoid Dose Thresholds Associated With All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Inmaculada del Rincon et al.
ARTHRITIS & RHEUMATOLOGY (2014)
HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab
Hennie G. Raterman et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Cardiovascular comorbidities antedating the diagnosis of rheumatoid arthritis
Anne M. Kerola et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Inflammation and immune system interactions in atherosclerosis
Bart Legein et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2013)
Pathophysiology of Atherosclerosis Plaque Progression
Kenichi Sakakura et al.
HEART LUNG AND CIRCULATION (2013)
Cyclosporine Induces Endothelial Cell Release of Complement-Activating Microparticles
Brandon Renner et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm
Jamie Robertson et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis
Katherine P. Liao et al.
RHEUMATOLOGY (2013)
Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion
Inge A. M. van den Oever et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2013)
How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?
Anne M. Kerola et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies
Juan Antonio Avina-Zubieta et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment
Sylvain Mathieu et al.
RHEUMATOLOGY (2012)
Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT)
Nehal N. Mehta et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2012)
Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease
Renata Micha et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
Rebecca Davies et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study
Jesper Lindhardsen et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease
Elena Myasoedova et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
B1a B Lymphocytes Are Atheroprotective by Secreting Natural IgM That Increases IgM Deposits and Reduces Necrotic Cores in Atherosclerotic Lesions
Tin Kyaw et al.
CIRCULATION RESEARCH (2011)
Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE
Deborah P. M. Symmons et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Total cholesterol and LDL levels decrease before rheumatoid arthritis
Elena Myasoedova et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity
Daniel H. Solomon et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
Richard J. Riese et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2010)
Leflunomide in the treatment of patients with early rheumatoid arthritis-results of a prospective non-interventional study
Herbert Kellner et al.
CLINICAL RHEUMATOLOGY (2010)
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
Sarah L. Westlake et al.
RHEUMATOLOGY (2010)
Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness
Anna Sodergren et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Effect of cyclosporine on blood pressure
Nadege Robert et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2010)
Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients
C. Popa et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Does Rheumatoid Arthritis Equal Diabetes Mellitus as an Independent Risk Factor for Cardiovascular Disease? A Prospective Study
Mike J. L. Peters et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis
I. Ikonomidis et al.
HEART (2009)
Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies
Christophe Meune et al.
RHEUMATOLOGY (2009)
Emerging Role of Interleukin-1 in Cardiovascular Diseases
B. Vicenova et al.
PHYSIOLOGICAL RESEARCH (2009)
Role of inflammation in atherosclerosis associated with rheumatoid arthritis
Peter Libby
AMERICAN JOURNAL OF MEDICINE (2008)
Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?
A. Gonzalez et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Atheroprotective Effects of Methotrexate on Reverse Cholesterol Transport Proteins and Foam Cell Transformation in Human THP-1 Monocyte/Macrophages
Allison B. Reiss et al.
ARTHRITIS AND RHEUMATISM (2008)
Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis
Ignatios Ikonomidis et al.
CIRCULATION (2008)
Atherosclerosis as a disease of failed endogenous repair
Andrey G. Zenovich et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis
Miguel A. Gonzalez-Gay et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2008)
Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis
Calin Popa et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
The widening mortality gap between rheumatoid arthritis patients and the general population
Angel Gonzalez et al.
ARTHRITIS AND RHEUMATISM (2007)
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy -: Results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS AND RHEUMATISM (2007)
Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis
Lennart T. H. Jacobsson et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis
Miguel A. Gonzalez-Gay et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis
V. P. van Halm et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study
Hilary A. Capell et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis
C. Turesson et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Patterns of cardiovascular risk in rheumatoid arthritis
D. H. Solomon et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study
Vokko P. van Halm et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Molecular evidence for arterial repair in atherosclerosis
R Karra et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Mechanisms of disease - Inflammation, atherosclerosis, and coronary artery disease
GK Hansson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
SD Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
TNF-α, rheumatoid arthritis, and heart failure:: a rheumatological dilemma
P Sarzi-Puttini et al.
AUTOIMMUNITY REVIEWS (2005)
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis - A population-based cohort study
H Maradit-Kremers et al.
ARTHRITIS AND RHEUMATISM (2005)
The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules
A Johnston et al.
CLINICAL IMMUNOLOGY (2005)
Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review
SL Whittle et al.
RHEUMATOLOGY (2004)
Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis?
S Dimmeler et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2004)
The safety of anakinra in high-risk patients with active rheumatoid arthritis - Six-month observations of patients with comorbid conditions
MH Schiff et al.
ARTHRITIS AND RHEUMATISM (2004)
Explaining how high-grade systemic inflammation accelerates vascular risk in rheumatoid arthritis
N Sattar et al.
CIRCULATION (2003)
Circulating endothelial cells are a novel marker of cyclosporine-induced endothelial damage
A Woywodt et al.
HYPERTENSION (2003)
Methotrexate and mortality in patients with rheumatoid arthritis:: a prospective study
HK Choi et al.
LANCET (2002)
Share Paper
